The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00588705
Recruitment Status : Completed
First Posted : January 8, 2008
Last Update Posted : January 30, 2017
Monash University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Brief Summary:

The purpose of this study is to first understand how MSKCC Clinical Genetics Service doctors talk to women with breast cancer about any genetic risks they might carry, and if they help women to think about what they might say, in turn, to their relatives, especially their daughters.

A second part of the study asks women for their opinions about when and how their daughters should be told about any genetic risks.

All of this will help us develop teaching methods to help our doctors improve the way they talk about genetic risk when women with breast cancer have adolescent daughters.

Condition or disease Intervention/treatment
Breast Cancer Counseling Behavioral: focus group & questionaire

Study Type : Observational
Actual Enrollment : 27 participants
Observational Model: Family-Based
Time Perspective: Prospective
Official Title: The Communication of Genetic Risk to Adolescent Daughters of Women With Breast Cancer
Study Start Date : December 2007
Actual Primary Completion Date : January 2017
Actual Study Completion Date : January 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Group/Cohort Intervention/treatment
focus group & questionaire
The group will discuss its views about how and when to talk about the risk of getting breast cancer. The focus group will be video recorded and the video recorded material will be later transcribed and carefully analyzed. In addition you will be asked to answer questions about yourself, such as education and marital status.
Behavioral: focus group & questionaire
The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.

Primary Outcome Measures :
  1. Is a demonstration of the effectiveness of the module in changing the behavior of clinicians after taking part in the communication skills module. [ Time Frame: conclusion of study ]

Secondary Outcome Measures :
  1. To examine the views of women about the provision of genetic risk information to their daughters. [ Time Frame: conclusion of study ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   12 Years to 20 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Memorial Sloan-Kettering Cancer Center (MSK) breast cancer patients seen by the clinical genetics service (CGS)and their daughters

Inclusion Criteria:

  • Women seen in the MSK CGS Service who have a diagnosis of breast cancer or
  • a family history of breast cancer and
  • have biological daughter(s) in the age range 12-20 years will be eligible to participate in Phase I & II.
  • Women who were consented to Phase I will automatically be eligible for Phase II.

Exclusion Criteria:

  • Women seen in the MSK CGS Service will be ineligible if they have no diagnosis of breast cancer and no family history of breast cancer,
  • do not have a biological daughter,
  • or have a biological daughter fewer than 12 or greater than 20 years(unless they were consented to Phase 1).
  • Women will be ineligible if they are not English speaking,
  • have intellectual or cognitive impairment,
  • or active mental illness rendering them incapable of giving informed consent, such as might occur with active psychosis.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00588705

United States, New York
Memorial Sloan-Kettering Cancer Center
New York, New York, United States, 10065
Sponsors and Collaborators
Memorial Sloan Kettering Cancer Center
Monash University
Principal Investigator: Smita Banerjee, PhD Memorial Sloan Kettering Cancer Center

Additional Information:
Responsible Party: Memorial Sloan Kettering Cancer Center Identifier: NCT00588705     History of Changes
Other Study ID Numbers: 07-063
First Posted: January 8, 2008    Key Record Dates
Last Update Posted: January 30, 2017
Last Verified: January 2017

Keywords provided by Memorial Sloan Kettering Cancer Center:
genetic risk
Genetic Counseling

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases